Published in AIDS Weekly, January 7th, 2002
The study of patients new to HIV therapy showed that of those who experienced viral rebound (HIV RNA >400 copies/mL), no patient (0/40) treated with a Kaletra-based regimen was found to have protease inhibitor-resistant HIV by genotypic analysis, compared to 33% (28/84) of patients treated with a nelfinavir-based regimen. These findings for Kaletra also were confirmed by phenotypic analysis in 37 patients for whom phenotype was available.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.